Search

Your search keyword '"Packard, Chris J"' showing total 681 results

Search Constraints

Start Over You searched for: Author "Packard, Chris J" Remove constraint Author: "Packard, Chris J"
681 results on '"Packard, Chris J"'

Search Results

3. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.

8. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

9. Biosynthesis and Metabolism of ApoB-Containing Lipoproteins.

10. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

11. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

12. Genome of The Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels.

13. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

14. Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use

15. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes

18. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.

21. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

25. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

27. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations

29. Response by Vallejo-Vaz et al to Letters Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up”

31. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

35. Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism

36. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up

40. Rare and low-frequency coding variants alter human adult height

42. Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism

43. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

49. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Catalog

Books, media, physical & digital resources